Continuing to look at external innovation to bolster its pipeline, Sanofi has paid Denali Therapeutics US$125 M upfront for its receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors for the treatment of neurological and systemic inflammatory diseases, including Alzheimer’s disease, multiple sclerosis and rheumatoid arthritis. The potential US$1.2 B deal comes amid a year of restructuring and strategic overhaul for Sanofi and just months after selling its European generics business. For Denali the deal follows another potential billion-dollar deal signed with Takeda earlier in the year.